Drug Profile
Sodium phenylbutyrate - Access Pharmaceuticals
Alternative Names: EL 532; Phenylbutyrate - Access; VP 101; VP 1301Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Virium Pharmaceuticals
- Developer Access Pharmaceuticals
- Class Antineoplastics; Electrolytes; Phenylbutyrates; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Colorectal cancer; Glioblastoma; Haematological malignancies; Prostate cancer; Radiation-induced skin damage
Most Recent Events
- 31 Mar 2011 Discontinued - Phase-II for Colorectal cancer in USA (IV)
- 31 Mar 2011 Discontinued - Phase-II for Colorectal cancer in USA (PO)
- 31 Mar 2011 Discontinued - Phase-II for Glioblastoma in USA (IV)